Last reviewed · How we verify
NCT04915859: SHE-Cool
Semiconductor Heat Extraction Cooling
NA trial testing Hand Cooling at 12-15 degrees celsius in Hyperthermia in 24 participants. Completed in 31 January 2022.
31 January 2022
Quick facts
| Lead sponsor | University of Connecticut |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 24 |
| Start date | 4 October 2021 |
| Primary completion | 31 January 2022 |
| Estimated completion | 31 January 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hand Cooling at 12-15 degrees celsius
- Hand Cooling at 16-20 degrees celsius
- hand and back cooling at 12-15 or 16-20 degrees celsius
- Passive cooling
Conditions studied
- Hyperthermia — all drugs for Hyperthermia →
Sponsor
University of Connecticut
Who can join
Adults 18 to 45, any sex, with Hyperthermia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heat-related injuries and other physiological stresses continue to be a significant threat to the health and operational effectiveness of the US Armed Forces (Armed Forces Health Surveillance 2011). This is because military personnel are exposed to exertional and environmental heat-stress factors during both deployment and training at US installations in hot and humid climates. Cold water immersion (CWI) is considered the gold standard for the treatment of exertional heat stroke (EHS) and has been shown to increase survival rates to 100% with the implementation of CWI best practices. However, in a field setting other cooling strategies have been developed to aid in the prevention of EHS and other heat-related illnesses. One such proposed strategy is a portable hand cooling device that does not require the use of ice or water. Therefore, the primary purpose of this investigation is to validate hand and back cooling devices using physiological, cognitive, performance, and perceptual responses that occur during and following rest, exercise, and cooling in the heat.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04915859
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperthermia
Currently open trials in the same condition.
- NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
- NCT06961929 — IEEM-Heat and Heart Failure · NA · recruiting
- NCT06966336 — IEEM- Work:Rest Cycles in Burn Survivors- Humidity · recruiting
- NCT07433036 — The Effectiveness of Emergency Room Protocols for Treating Hyperthermia · NA · recruiting
- NCT06842784 — Impact of Extreme Heat on Myocardial Blood Flow and Flow Reserve in Young and Older Adults · recruiting
Other University of Connecticut trials
Trials by the same sponsor.
- NCT06794840 — JomCare Study - A Harm Reduction Study · NA · not yet recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT06381921 — Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain · NA · recruiting
- NCT06393725 — Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions · NA · recruiting
- NCT04989309 — Left and Right Hemisphere Contributions to Speech Perception · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04915859 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Connecticut
- Last refreshed: 31 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04915859.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing